Innoviva Shares Outstanding 2010-2024 | INVA

Innoviva shares outstanding from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Innoviva Annual Shares Outstanding
(Millions of Shares)
2023 87
2022 95
2021 94
2020 114
2019 113
2018 113
2017 120
2016 123
2015 115
2014 112
2013 102
2012 91
2011 82
2010 72
2009 63
Innoviva Quarterly Shares Outstanding
(Millions of Shares)
2024-09-30 63
2024-06-30 63
2024-03-31 85
2023-12-31 87
2023-09-30 86
2023-06-30 65
2023-03-31 90
2022-12-31 95
2022-09-30 96
2022-06-30 96
2022-03-31 94
2021-12-31 94
2021-09-30 82
2021-06-30 101
2021-03-31 114
2020-12-31 114
2020-09-30 114
2020-06-30 114
2020-03-31 114
2019-12-31 113
2019-09-30 113
2019-06-30 113
2019-03-31 113
2018-12-31 113
2018-09-30 113
2018-06-30 113
2018-03-31 114
2017-12-31 120
2017-09-30 120
2017-06-30 120
2017-03-31 120
2016-12-31 123
2016-09-30 122
2016-06-30 124
2016-03-31 113
2015-12-31 115
2015-09-30 116
2015-06-30 115
2015-03-31 115
2014-12-31 112
2014-09-30 113
2014-06-30 111
2014-03-31 110
2013-12-31 102
2013-09-30 106
2013-06-30 98
2013-03-31 96
2012-12-31 96
2012-09-30 95
2012-06-30 89
2012-03-31 92
2011-12-31 82
2011-09-30 82
2011-06-30 82
2011-03-31 81
2010-12-31 72
2010-09-30 74
2010-06-30 73
2010-03-31 65
2009-12-31 63
2009-09-30 63
2009-06-30 63
2009-03-31 62
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.117B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $728.847B 75.49
Novo Nordisk (NVO) Denmark $381.440B 27.51
Johnson & Johnson (JNJ) United States $347.829B 14.11
AbbVie (ABBV) United States $310.275B 16.33
Merck (MRK) United States $248.031B 16.48
AstraZeneca (AZN) United Kingdom $202.626B 17.24
Novartis AG (NVS) Switzerland $198.493B 13.19
Pfizer (PFE) United States $149.382B 10.22
Sanofi (SNY) $121.080B 10.97
Bayer (BAYRY) Germany $19.295B 3.09